Skip to content

Protagonist Therapeutics

US · PTGX #1570 by market cap Listed 2016
121.40 -2.62 -2.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 125.25 +0.99%
After-hours 121.40 0.00%
158.6293.23121.402026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on PTGX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +12.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 15.8% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation D-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 25.7x Better than 29%
Forward P/E 45.9x Better than 8%
Price / Sales 15.5x Better than 7%
P/E vs own 5-yr range 78th pctl Better than 28%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Operating margin -343.6% Better than 4%
Net margin -282.8% Better than 4%
Return on equity -20.2% Better than 16%
Return on invested capital -23.1% Better than 12%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -21.3% Better than 29%
6-month return 22.4% Better than 85%
12-month return (ex latest month) 62.1% Better than 88%
Distance below 52-week high 24.5% Better than 51%
Financial Health B-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 12.7x Better than 95%
Debt to assets 1.5% Better than 90%
Interest coverage -107.4x Better than 5%
Free cash flow / net income 66.4% Better than 20%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 48.3% Better than 65%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -7.29%
1M -12.02%
3M -19.44%
6M +20.34%
YTD +39.00%
1Y +44.18%
3Y +604.18%
5Y +246.56%

Key statistics

Price & volume

Prev close
124.02
Open
123.41
Day range
120.15 - 125.91
Avg price
122.73
Volume
600.73K
Turnover
73.73M
Amplitude
4.65%
52-week range
77.00 - 160.81

Valuation

P/E
-59.22
P/E (TTM)
25.67
P/B
7.30
EPS
-2.05
Net profit
-133.80M
Net assets
1.08B

Share structure

Market cap
7.92B
Float cap
6.48B
Shares out
65.27M
Float shares
53.36M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2016-08-11
52-week range 53% of range
77.00 160.81

24.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-3.23M net over the window

Short interest

Shares short
10.24M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Protagonist Therapeutics (PTGX)?

Protagonist Therapeutics last traded at 121.40. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Protagonist Therapeutics's market cap?

About 7.92B.

What is the P/E ratio of Protagonist Therapeutics?

The trailing twelve-month P/E is 25.67, above its own 5-year average of 16.61 — toward the top of its historical range (78.31% percentile). See the Valuation tab for the full history.

Does Protagonist Therapeutics pay a dividend?

Protagonist Therapeutics does not currently pay a regular dividend.

Is Protagonist Therapeutics a buy according to analysts?

The consensus of 13 analysts is a Buy rating, with an average 12-month price target of 180.00, which implies 48.3% upside from the current price. This is not investment advice.

What is Protagonist Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Protagonist Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Protagonist Therapeutics discussion 0 comments

Add a comment